https://www.coltonconsortium.org/directory/christoph-ellebrecht-md/
Assistant Professor, Department of Dermatology, Perelman School of Medicine, University of Pennsylvania Dr. Christoph Ellebrecht is an Assistant Professor of Dermatology at the Perelman School of Medicine, University of Pennsylvania, […]
https://www.coltonconsortium.org/directory/jill-p-buyon-md/
Sir Deryck and Lady Va Maughan Professor of Rheumatology, Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health Director, Division of Rheumatology, NYU Grossman School of Medicine […]
https://www.coltonconsortium.org/directory/christopher-pittenger-md-phd/
Elizabeth Mears and House Jameson Professor, Department of Psychiatry, Yale School of Medicine, Yale University Dr. Christopher Pittenger is the Mears & Jameson Professor and Deputy Chair for Translational Research […]
https://www.coltonconsortium.org/directory/joseph-craft-md/
Paul B. Beeson Professor of Medicine (Rheumatology), Department of Internal Medicine (Rheumatology, Allergy & Immunology), Yale School of Medicine, Yale University Professor of Immunobiology, Department of Immunobiology, Yale School of […]
https://www.coltonconsortium.org/projects/the-epidermis-as-a-novel-therapeutic-target-in-pemphigus-vulgaris/
By profiling genetic and molecular drivers of pemphigus vulgaris across patient skin and blood, this project uncovers genotype-driven inflammatory loops and actionable targets for personalized therapy.
https://www.coltonconsortium.org/projects/the-role-of-glycosylation-in-inflammatory-bowel-disease/
Investigating how foreign sugar modifications on anti-TNF biologics trigger immune responses in pediatric IBD patients, this project aims to personalize biologic therapy selection and inform safer drug design.
https://www.coltonconsortium.org/projects/targeted-biologic-therapy-for-autoimmune-disease-associated-with-dnaseil3-deficiency/
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
https://www.coltonconsortium.org/projects/therapeutic-targeting-of-thromboangioplasticity-in-autoimmune-antiphospholipid-syndrome/
Restoring thromboangioplasticity in antiphospholipid syndrome by developing recombinant proteins that counteract harmful anti-annexin V antibodies.
https://www.coltonconsortium.org/projects/inhibiting-netosis-with-nuclear-penetrating-antibodies/
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
https://www.coltonconsortium.org/projects/small-molecule-strategies-to-induce-antigen-specific-b-cell-tolerance/
Developing novel multivalent small molecules that selectively silence or eliminate the autoantibody-producing B cells driving autoimmune disease.